Orphazyme A/S Overview
Latest ROE for Orphazyme A/S: -10.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-10.23%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Orphazyme A/S posts a ROE of -10.23%. That is below the Healthcare sector average of 11.15%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 11.15% is typical. Orphazyme A/S's -10.23% is lower that level. That is roughly 191.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Orphazyme A/S's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -10.23%; use YoY and peer views to separate noise from signal.
Context for ORPHY's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.15%), and (3) consistency with growth and profitability. This page covers the first two; Orphazyme A/S's other metric pages and overview cover the third.
Judging Orphazyme A/S against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -10.23% here, then scan peer and history charts to see if the gap is persistent.
